Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Doxorubicin, Prednisolone, Rituximab, and Vincristine in patients with Diffuse Large B-Cell Lymphoma.

Statements

Source and description
Rituxan (rituximab) [product monograph]. HC. Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP chemotherapy.